Finally, we demonstrated that neither the expression of PPARγ nor the expression of the inactivated form of the receptor, that is, phosphorylated PPARγ, were significantly different in tumours from RGZ-treated and solvent-treated mice, thus suggesting that the binding capacity of this molecule to its receptor was maintained throughout the entire treatment period. Here, PPARG is linked to neoplasm.